Raymond James Financial Inc. Invests $2.22 Million in Twist Bioscience Co. (NASDAQ:TWST)

Raymond James Financial Inc. acquired a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 47,863 shares of the company’s stock, valued at approximately $2,224,000. Raymond James Financial Inc. owned 0.08% of Twist Bioscience as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience during the 3rd quarter worth approximately $34,000. Van ECK Associates Corp increased its position in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares during the period. US Bancorp DE lifted its stake in Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC acquired a new position in shares of Twist Bioscience during the third quarter valued at $95,000. Finally, KBC Group NV boosted its holdings in shares of Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after acquiring an additional 1,226 shares during the period.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,726 shares of Twist Bioscience stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the transaction, the chief executive officer now owns 660,966 shares of the company’s stock, valued at approximately $27,549,062.88. This trade represents a 0.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Paula Green sold 918 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the sale, the senior vice president now owns 130,912 shares in the company, valued at approximately $5,355,609.92. The trade was a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,799 shares of company stock worth $1,593,944 in the last ninety days. 3.01% of the stock is currently owned by corporate insiders.

Twist Bioscience Stock Down 2.9 %

Shares of TWST stock opened at $40.36 on Monday. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The business’s fifty day moving average is $45.15 and its 200-day moving average is $45.37. The stock has a market cap of $2.41 billion, a PE ratio of -11.94 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period in the previous year, the company earned ($0.75) earnings per share. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. Equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird lifted their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.